Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers
Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers
NCT ID: NCT05148962 Phase: PHASE1 Status: COMPLETED Enrollment: 45 Completion: 2023-05-26
Conditions
COVID-19
Interventions
GRT-R910
Summary
The primary objective was to assess the safety and tolerability of 2 different doses (10 or 30 µg) of GRT-R910 when administered as a boost in healthy adults previously vaccinated with the AstraZeneca, Janssen/Johnson and Johnson, Moderna, or Pfizer/BioNTech Coronavirus disease 2019 (COVID-19) vaccines.
Primary Outcome
Number of Participants With at Least One Solicited Local Adverse Event (AE) Within 8 Days After the Injection of Prime Dose